ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,62
0,44%
Dow Jones
44 424,25
-0,32%
DAX
21 394,93
-0,11%
Brent Oil
77,625
0,00%
Bitcoin
104 763,05
0,03%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. CNS Pharmaceuticals Inc (CNSP)

  7. CNS Pharmaceuticals Inc (CNSP) Actualités

CNSP

CNS Pharmaceuticals (CNSP)

CNS Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CNSP
DateHeureSourceTitreSymboleSociété
11/12/202418h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNSPCNS Pharmaceuticals Inc
15/11/202422h19Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:CNSPCNS Pharmaceuticals Inc
14/11/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNSPCNS Pharmaceuticals Inc
28/10/202421h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
24/10/202417h23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNSPCNS Pharmaceuticals Inc
15/10/202423h24Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
03/09/202414h00GlobeNewswire Inc.IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.NASDAQ:CNSPCNS Pharmaceuticals Inc
06/08/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
06/08/202422h53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
05/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNSPCNS Pharmaceuticals Inc
02/08/202422h11Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:CNSPCNS Pharmaceuticals Inc
31/07/202418h32Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:CNSPCNS Pharmaceuticals Inc
30/07/202423h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNSPCNS Pharmaceuticals Inc
19/07/202423h12Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
12/07/202422h30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202423h28Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
31/01/202422h27Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CNSPCNS Pharmaceuticals Inc
13/10/202300h01Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314h40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314h39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202323h11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNSPCNS Pharmaceuticals Inc
02/05/202301h00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNSPCNS Pharmaceuticals Inc
31/03/202323h05Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
29/03/202315h05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight EventNASDAQ:CNSPCNS Pharmaceuticals Inc
13/03/202312h05PR Newswire (US)CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank IssuesNASDAQ:CNSPCNS Pharmaceuticals Inc
09/03/202315h05PR Newswire (US)CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandNASDAQ:CNSPCNS Pharmaceuticals Inc
14/02/202318h24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNSPCNS Pharmaceuticals Inc
07/02/202314h45PR Newswire (US)CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMNASDAQ:CNSPCNS Pharmaceuticals Inc
12/01/202314h45PR Newswire (US)CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandNASDAQ:CNSPCNS Pharmaceuticals Inc
05/01/202315h05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:CNSPCNS Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CNSP

Dernières Valeurs Consultées

LSE
FDM
Fdm Group (holdings)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés